SynAct Pharma AB

BATS-CHIXE:SYNACS Stock Report

Market Cap: SEK 1.0b

SynAct Pharma Valuation

Is SYNACS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of SYNACS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate SYNACS's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate SYNACS's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYNACS?

Key metric: As SYNACS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SYNACS. This is calculated by dividing SYNACS's market cap by their current book value.
What is SYNACS's PB Ratio?
PB Ratio5.9x
BookSEK 170.29m
Market CapSEK 1.01b

Price to Book Ratio vs Peers

How does SYNACS's PB Ratio compare to its peers?

The above table shows the PB ratio for SYNACS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average461x
BVXP Bioventix
7.2xn/aUK£83.6m
4BB 4basebio
4.5xn/aUK£85.1m
AVCT Avacta Group
1822.5x13.80%UK£262.4m
AREC Arecor Therapeutics
9.6xn/aUK£27.4m
SYNACS SynAct Pharma
5.9x46.77%SEK 1.0b

Price-To-Book vs Peers: SYNACS is good value based on its Price-To-Book Ratio (5.9x) compared to the peer average (480x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does SYNACS's PB Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / BookEstimated GrowthMarket Cap
TRX Tissue Regenix Group
0.2xn/aUS$6.98m
DEST Destiny Pharma
0.3x-15.52%US$5.85m
ROQ Roquefort Therapeutics
0.3xn/aUS$2.22m
LLAI LungLife AI
0.2xn/aUS$1.72m
No. of Companies5PB01.63.24.86.48+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: SYNACS is expensive based on its Price-To-Book Ratio (5.9x) compared to the UK Biotechs industry average (3.4x).

Price to Book Ratio vs Fair Ratio

What is SYNACS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYNACS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SYNACS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SYNACS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
SEK 33.45
0%
10.31%SEK 36.90SEK 30.00n/a2
Feb ’27SEK 20.80
SEK 31.45
+51.20%
17.33%SEK 36.90SEK 26.00n/a2
Jan ’27n/a
SEK 31.45
0%
17.33%SEK 36.90SEK 26.00n/a2
Dec ’26n/a
SEK 31.45
0%
17.33%SEK 36.90SEK 26.00n/a2
Nov ’26n/a
SEK 31.45
0%
17.33%SEK 36.90SEK 26.00n/a2
SEK 36.7
Fair Value
43.3% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/25 07:35
End of Day Share Price 2026/01/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SynAct Pharma AB is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrik LingDNB Carnegie
Jyoti PrakashEdison Investment Research
Carl RamaniusRedeye